Allogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age
10.3760/cma.j.issn.0254-1785.2011.08.010
- VernacularTitle:异基因造血干细胞移植治疗50岁以上恶性血液病患者35例
- Author:
Xiaojin WU
;
Xiao MA
;
Yuejun LIU
;
Ye ZHAO
;
Xiaohui HU
;
Haixia ZHOU
;
Yue HAN
;
Xiaowen TANG
;
Zhengzheng FU
;
Huiying QIU
;
Aining SUN
;
Depei WU
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Hematologic neoplasms
- From:
Chinese Journal of Organ Transplantation
2011;32(8):485-487
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficiency and safety of allogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 yeas of age. Methods From May 2002 to January 2010, 35 patients (＞ 50 years) with malignant hematological diseases received allogeneic hematopoietic cell transplantation. In 35 patients, 18 patients were conditioned with non-myeloablative regimen and 17 patients with myeloablative regimen. The outcome,engraftment and prognosis of allogeneic hematopoietic cell transplantation were analyzed. Results The hematopoetic reconstitution was achieved in 32 of 35 patients. The median time of granulocyte count exceeding 0. 5 × 109/L was 12 days and the that of platelet count exceeding 20 × 109/L was 17days. The cumulative incidence of aGVHD was 48. 6 %, and 37. 9 % patients developed cGVHD.The estimate probability of cumulative survival at 5 years was 48. 5 %, The estimate probability of cumulative mortality rate was 51.5 %, and the estimated transplant-related mortality was 22. 9 %.The relapse rate was 11.4 %. There was significant difference except for the incidence of cGVHD.Conclusion Allogeneic hematopoietic cell transplantation may be appropriate for older patients with malignant hematological diseases.
